{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:39:41Z","timestamp":1792705181692,"version":"4.5.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"DOI":"10.1038\/s41375-026-03178-9","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:42:36Z","timestamp":1792658556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Concordance between bone marrow and blood measurable residual disease after first-line novel agent treatment for chronic lymphocytic leukemia: a systematic review and meta-analysis"],"prefix":"10.1038","author":[{"given":"Giuseppe","family":"Fiorica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2321-1970","authenticated-orcid":false,"given":"Graham","family":"Wehmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1601-9163","authenticated-orcid":false,"given":"Claire I.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6538-666X","authenticated-orcid":false,"given":"Diana","family":"Segovia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto Alfredo","family":"Rios-Olais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8249-4128","authenticated-orcid":false,"given":"Talal","family":"Hilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kittai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"3178_CR1","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/s41375-026-02970-x","volume":"40","author":"Y Wang","year":"2026","unstructured":"Wang Y, Li C, Gale RP, Liang Q, Kay NE, Huang Q, et al. Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies. Leukemia. 2026;40:1439\u201347.","journal-title":"Leukemia"},{"key":"3178_CR2","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2024.2122","volume":"10","author":"FA Rios-Olais","year":"2024","unstructured":"Rios-Olais FA, McGary AK, Tsang M, Almader-Douglas D, Leis JF, Buras MR, et al. Measurable residual disease and clinical outcomes in chronic lymphocytic leukemia: a systematic review and meta-analysis. JAMA Oncol. 2024;10:1221\u20137.","journal-title":"JAMA Oncol"},{"key":"3178_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"key":"3178_CR4","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1182\/blood.2024024631","volume":"144","author":"O Al-Sawaf","year":"2024","unstructured":"Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood. 2024;144:1924\u201335.","journal-title":"Blood"},{"key":"3178_CR5","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","volume":"107","author":"C Moreno","year":"2022","unstructured":"Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica. 2022;107:2108\u201320.","journal-title":"Haematologica"},{"key":"3178_CR6","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","volume":"388","author":"B Eichhorst","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP, Furstenau M, von Tresckow J, Zhang C, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388:1739\u201354.","journal-title":"N Engl J Med"},{"key":"3178_CR7","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1200\/JCO.22.02283","volume":"41","author":"T Munir","year":"2023","unstructured":"Munir T, Moreno C, Owen C, Follows G, Benjamini O, Janssens A, et al. Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study. J Clin Oncol. 2023;41:3689\u201399.","journal-title":"J Clin Oncol"},{"key":"3178_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15:155\u201363.","journal-title":"J Chiropr Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03178-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03178-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03178-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:02:09Z","timestamp":1792702929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03178-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":8,"alternative-id":["3178"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03178-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"14 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TH has consulted for BeOne, Incyte, BMS\/Celgene, and AstraZeneca, and has received research funding from BeOne, BMS\/Celgene, Regenerom, Kite\/Gilead, Qurient, Genmab, and Lyell. ASK has consulted for Abbvie, AstraZeneca, Genmab, Invivyd, and Pfizer, and has received honoraria from AstraZeneca and Eli Lilly.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}